TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06767540: A Randomized Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of AK120 in the Treatment of Moderate-to-severe Atopic Dermatitis (AD) in Adolescents

Sponsor: Akeso · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 198 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,594,480

Rescue Site Savings

+$4,359,684

Unlock Full NCT06767540 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06767540 Rescue Dossier →